A New Paradigm for Treating Refractory Solid Tumors

GenomeFrontier Therapeutics, Inc., dedicates to develop next-generation CAR-T cell therapy with high potency, specificity, durability, and safety, thus achieving a sustained anti-tumor response to treat cancer effectively.

螢幕快照 2019-06-14 下午5.01.13.png

We leverage four proprietary non-viral gene and cell engineering technologies in the chimeric antigen receptor (CAR) T cell therapies for cancer treatment.  Our core technology and platforms are fully IP protected for non-viral genetic engineering, cellular expansion and optimization. GF devotes to develop state-of-the-art products and platforms for next-generation CAR-T cell therapy with high potency, specificity, durability, and safety, thus achieving a sustained anti-tumor response capable of conquering cancer.